A difference of 25 to 45 percentage points could matter when a person with an inherited BRCA2 change weighs breast cancer screening or preventive surgery. Mayo Clinic researchers have identified 70 BRCA2 variants linked to a moderate, rather than very high, lifetime risk of breast cancer.

BRCA2 helps cells repair damaged DNA. Some inherited changes in the gene can disrupt that work and raise cancer risk, but the new study shows that not all harmful changes have the same effect. The researchers call the 70 variants “hypomorphic”: they weaken BRCA2’s function only partly. The study, published in Nature Communications, also describes them as reduced-penetrance pathogenic variants, meaning disease-causing changes that do not carry the highest level of risk.

People who inherit the specific variants are estimated to have a 20% to 25% lifetime chance of developing breast cancer, the researchers report. For people with more common harmful BRCA2 variants, the estimated lifetime risk is 50% to 70%. To reach their findings, the team studied how the variants affect BRCA2’s function and analyzed genetic testing data from a large number of people who had undergone hereditary cancer testing. Mayo Clinic researchers worked with investigators from Ambry Genetics.

The distinction could help patients and care teams make decisions based on a more accurate estimate of risk. Carriers of these variants may still qualify for and benefit from regular mammograms and breast MRI scans, the researchers say. But a clearer picture of each person’s risk could also help inform discussions about risk-reducing surgery.

“This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk,” says Fergus Couch, a breast cancer researcher at Mayo Clinic Comprehensive Cancer Center. Couch says matching prevention and screening to a person’s specific variant may help avoid treating every BRCA2 result as if it carried identical risk. The study also notes that a small subset of breast cancers may be caused by these partly functioning BRCA2 variants.

The team explored a possible treatment connection, too. Some tumors linked to the variants may respond to PARP inhibitors, targeted drugs that interfere with cancer cells’ ability to repair damaged DNA. The findings do not mean every such tumor will respond; tumor testing may help doctors decide whether the drugs are suitable for an individual patient.

Researchers are continuing to identify and study partly functioning variants in both BRCA2 and BRCA1, another gene linked to inherited breast cancer risk. Couch says identifying all of these variants could allow teams to define risk management and treatment strategies more precisely. For now, the results offer a useful reminder for patients and clinicians: a genetic risk estimate can depend on the exact change, not just the name of the gene.